ZA200902814B - Compositions and methods for diagnosing, treating, and preventing prostate conditions - Google Patents

Compositions and methods for diagnosing, treating, and preventing prostate conditions

Info

Publication number
ZA200902814B
ZA200902814B ZA200902814A ZA200902814A ZA200902814B ZA 200902814 B ZA200902814 B ZA 200902814B ZA 200902814 A ZA200902814 A ZA 200902814A ZA 200902814 A ZA200902814 A ZA 200902814A ZA 200902814 B ZA200902814 B ZA 200902814B
Authority
ZA
South Africa
Prior art keywords
diagnosing
compositions
treating
methods
preventing prostate
Prior art date
Application number
ZA200902814A
Other languages
English (en)
Inventor
Carlton D Donald
Original Assignee
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev filed Critical Musc Found For Res Dev
Publication of ZA200902814B publication Critical patent/ZA200902814B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200902814A 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions ZA200902814B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88514207P 2007-01-16 2007-01-16

Publications (1)

Publication Number Publication Date
ZA200902814B true ZA200902814B (en) 2010-08-25

Family

ID=39636676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902814A ZA200902814B (en) 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions

Country Status (16)

Country Link
US (3) US8088603B2 (fr)
EP (1) EP2104744B1 (fr)
JP (1) JP5653042B2 (fr)
KR (1) KR101565080B1 (fr)
CN (1) CN101970685B (fr)
AP (1) AP2009004851A0 (fr)
AU (1) AU2008206258B2 (fr)
BR (1) BRPI0806779A2 (fr)
CA (1) CA2667364A1 (fr)
ES (1) ES2390083T3 (fr)
HK (1) HK1154052A1 (fr)
IL (1) IL198677A (fr)
MX (1) MX2009007564A (fr)
NZ (2) NZ596471A (fr)
WO (1) WO2008089236A2 (fr)
ZA (1) ZA200902814B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
US20120071347A1 (en) * 2005-10-14 2012-03-22 Phigenix, Inc. Compositions and methods for monitoring and detecting cancerous conditions
RU2016133412A (ru) * 2009-08-24 2018-12-10 Фидженикс, Инк. Целенаправленное воздействие на pax2 для лечения рака молочной железы
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
WO2013085483A1 (fr) * 2011-12-05 2013-06-13 Phigenix, Inc. Ciblage de en2, de pax2 et/ou de defb1pour le traitement d'états pathologiques de la prostate
WO2013188789A2 (fr) * 2012-06-14 2013-12-19 Whitehead Institute For Biomedical Research Procédé à l'échelle du génome d'évaluation d'interactions entre des entités chimiques et leurs molécules cibles
CN105452860B (zh) 2013-01-20 2019-08-02 戴埃克斯有限公司 Pkal-介导的病症的评估、测定和治疗
WO2015161189A1 (fr) * 2014-04-17 2015-10-22 Cornell University Neat1 utile en tant que marqueur de pronostic et cible thérapeutique pour le cancer de la prostate
EP3286565A1 (fr) * 2015-04-21 2018-02-28 Genentech, Inc. Compositions et procédés pour l'analyse du cancer de la prostate
CN108770366A (zh) * 2015-12-15 2018-11-06 凯斯西储大学 β防御素在上皮性癌评估中的应用
US11732258B2 (en) * 2016-11-02 2023-08-22 President And Fellows Of Harvard College Engineered guide RNA sequences for in situ detection and sequencing
CN111454916A (zh) * 2019-01-18 2020-07-28 王泽宋 甘油醛-3-磷酸脱氢酶蛋白或其免疫性片段的新应用
CN109781988A (zh) * 2019-02-28 2019-05-21 贵州省人民医院 采用her2基因扩增法检测乳腺癌循环肿瘤细胞的特异性方法
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)
CN110907650A (zh) * 2019-11-18 2020-03-24 复旦大学附属儿科医院 应用纳米磁珠富集尿液沉渣pax2蛋白作为诊断原发性膀胱输尿管反流生物标志物的用途
BR112022012075A2 (pt) 2019-12-17 2022-08-30 Chinook Therapeutics Inc Métodos para tratar nefropatia por iga com atrasentan
CN112646895A (zh) * 2021-01-22 2021-04-13 深圳科诺医学检验实验室 检测基因表达量的引物、探针、试剂盒、检测方法及应用
CN113658696B (zh) * 2021-07-22 2023-07-14 四川大学华西医院 一种基于患者年龄、营养指标、肿瘤分期和肿瘤标志物联合预测胃癌预后的预测系统
CN114045336B (zh) * 2021-09-28 2024-01-02 中国人民解放军空军军医大学 Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用
CN114113633B (zh) * 2021-12-27 2024-05-24 复旦大学 用于前列腺癌危险度诊断和疗效评估的分子指标、试剂盒
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用
CN117777234A (zh) * 2023-09-20 2024-03-29 烟台蓝纳成生物技术有限公司 丹磺酰胺修饰的psma靶向化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
CA2330929A1 (fr) * 1998-06-06 1999-12-16 Genostic Pharma Limited Sondes permettant de determiner un profil genetique
US6699973B1 (en) * 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
GB9903841D0 (en) * 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030092657A1 (en) * 1999-12-22 2003-05-15 Paul Goodyer Modulation of PAX-2 for controlled apoptosis or survival of cells
WO2002022884A2 (fr) * 2000-09-12 2002-03-21 Transgenetics Incorporated Organisation en micro-reseaux de genes cibles de facteur de transcription
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
EP1373896A2 (fr) * 2001-03-12 2004-01-02 MonoGen, Inc. Detection et differenciation d'etats pathologiques par echantillons cellulaires
AU2003287366A1 (en) * 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20060135422A1 (en) * 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
US8673634B2 (en) * 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
CA2599393A1 (fr) * 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Petites molecules inhibitrices du stat3 et leurs utilisations
US20070166728A1 (en) 2005-07-22 2007-07-19 Alphagenics, Inc. Genetic profile imaging and data-sharing device and methodology for socially relevant traits
CA2625891A1 (fr) * 2005-10-14 2007-04-26 Carlton D. Donald Ciblage de pax2 en vue d'induire le traitement du cancer et l'immunite tumorale induite par defb1

Also Published As

Publication number Publication date
HK1154052A1 (en) 2012-04-13
AP2009004851A0 (en) 2009-06-30
WO2008089236A2 (fr) 2008-07-24
US20110229492A1 (en) 2011-09-22
JP2010526278A (ja) 2010-07-29
IL198677A0 (en) 2010-02-17
AU2008206258B2 (en) 2013-06-13
EP2104744B1 (fr) 2012-05-16
NZ596471A (en) 2013-11-29
WO2008089236A3 (fr) 2010-01-07
ES2390083T3 (es) 2012-11-06
CN101970685B (zh) 2013-08-07
BRPI0806779A2 (pt) 2011-09-13
US8445444B2 (en) 2013-05-21
KR101565080B1 (ko) 2015-11-03
AU2008206258A1 (en) 2008-07-24
MX2009007564A (es) 2009-12-08
AU2008206258A2 (en) 2009-10-29
EP2104744A2 (fr) 2009-09-30
KR20090101442A (ko) 2009-09-28
EP2104744A4 (fr) 2011-05-04
CN101970685A (zh) 2011-02-09
US20100029560A1 (en) 2010-02-04
CA2667364A1 (fr) 2008-07-24
JP5653042B2 (ja) 2015-01-14
US8088603B2 (en) 2012-01-03
NZ578164A (en) 2011-12-22
IL198677A (en) 2013-03-24
US20120058130A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
ZA200902814B (en) Compositions and methods for diagnosing, treating, and preventing prostate conditions
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
PL3009148T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
IL197721A0 (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
EP2125887A4 (fr) Compositions et procedes utilises pour le diagnostic et le traitement du cancer
IL208366A0 (en) Compositions and methods for treating and diagnosing asthma
EP2260109A4 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
EP2155249A4 (fr) Compositions et procédés pour le diagnostic et le traitement du cancer
EP2271329A4 (fr) Procédés, compositions et kits pour traiter la douleur et le prurit
EP2323677A4 (fr) Compositions à base de micro-arn et procédés de diagnostic, de pronostic et de traitement d un myélome multiple
EP1945754A4 (fr) Compositions et méthodes pour traiter et diagnostiquer un cancer
HK1175792A1 (en) Compositions and methods for diagnosing and treating cancer
GB2466912B (en) Compositions and methods for treating lysosomal disorders
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2367939A4 (fr) Procédés pour le diagnostic ou le traitement d'un cancer de la prostate
EP2271370A4 (fr) Compositions et procédés pour diagnostiquer et traiter un mélanome
EP2101567A4 (fr) Compositions et procédés pour détecter, traiter ou prévenir le stress réductif
EP1977247A4 (fr) Procedes de diagnostic et de traitement du cancer de la prostate
EP2099491A4 (fr) Compositions et procedes pour diagnostiquer et traiter un cancer
EP2350318A4 (fr) Procédés, compositions et kits pour diagnostiquer, surveiller et traiter une maladie
EP2137213A4 (fr) Procédés et compositions pour le traitement du cancer de la prostate
HK1149770A1 (en) Compositions, methods and kits
EP2424549A4 (fr) Compositions et méthodes de traitement et de prévention des lithiases urinaires et des affections associées